Introduction {#S1}
============

Contrary to long held belief, adult neurogenesis (AN) is now a well-recognized phenomenon in mammals. While constitutively active AN is restricted to two forebrain regions, the subgranular zone (SGZ) of the dentate gyrus (DG) of the hippocampus and the subventricular zone (SVZ) lining the ventricles, variable degrees of reactive neurogenesis is present in several other brain regions that is activated in response to injury or disease onset ([@B78]). Importantly, impairments in AN have been linked to a number of neurological and psychiatric diseases ([@B71]; [@B140]), indicating the value of developing therapies that boost AN potential of cell replacement in tackling brain dysfunction.

In contrast to mammals, lower vertebrates such as teleost fish and amphibians (such as axolotl and salamander) have expanded neurogenic capacities. Unsurprisingly, most of our understanding of human AN processes continues to be informed by findings in lower vertebrate models that also display comparable expression patterns and functions of neurogenic molecular controls. Intriguingly, some amphibian species display life-long de-differentiation and *trans-*differentiation processes during repair (as seen during retinal and lens regeneration in newts), phenomenon absent in mammals. Using recently developed gene-editing toolkits, studies in these species can provide mechanistic insights into why such phenomenon are scaled down in mammals and be informative for developing novel disease relevant cell-replacement strategies.

The remarkable ability of the adult mammalian brain to functionally integrate new neurons into existing circuitries ([@B51]) combined with the progress in our understanding of these phenomenon in non-mammalian and mammalian models has now made possible the development of therapies that can awaken latent neurogenic programs, direct resident neuronal fates into cell types of need and replace injured or diseased neurons in brain regions within and outside that of DG and SVZ. This review discusses AN in mammalian and non-mammalian brains, the reparative potential of cell-based transplant therapy in neurodegenerative diseases and the therapeutic application of novel gene-editing approaches in the framework of designing disease- and patient-specific curative strategies ([Figure 1](#F1){ref-type="fig"}).

![Adult neurogenesis in mammals and non-mammals. Lessons from non-vertebrate neurogenesis and implications for designing cell-based transplant therapies. Mammalian SVZ Neurogenesis: Characterization of neurogenesis in the rodent SVZ has revealed the existence of quiescent and active populations of proliferating cells. While heterogenous populations of NSCs have been described, "type-B" cells maintaining close proximity with the ependymal cell layer include nestin-expressing populations that asymmetrically divide to form Ascli and Dlx2 expressing "type-C" cells, also called transit-amplifying cells, which then symmetrically divide to form Dcx-positive type-A neuroblasts. These neuroblasts constitute the rostral migratory stream (RMS) that eventually contributes to OB peri-glomerular and granule cells. Recent studies have suggested that "type-B" cells are derived from embryonic NSCs that also generate striatal, septal or cortical neurons and become quiescent between E13.5-15.5 until their activation in adulthood ([@B53]). Within the OB, granule cells form \>95% of the adult-born population ([@B178]; [@B113]; [@B107]). Optogenetic activation paired with odor stimulation of adult-born neurons has been shown to facilitate difficult olfactory discrimination learning, an effect that is absent following photoactivation of early postnatal born neurons ([@B1]). In addition, two photon-targeted recordings from peri-glomerular neurons have revealed that adult-born cells functionally integrate in the OB circuitry and whose activity is regulated by experience-dependent plasticity ([@B96]). Mammalian DG Neurogenesis: Whether the adult mammalian hippocampus contains self-renewing NSCs or whether the neighboring lateral ventricular niche containing true NSCs maintains neurogenesis in the hippocampus has been contested ([@B153]; [@B30]) but several recent studies have documented the presence of self-renewing, multipotent cells expressing embryonic NSC markers in the DG with fate mapping analysis confirming their stem cell behavior *in vivo* ([@B155]; [@B91]; [@B73]; [@B99]; [@B28]; [@B45]; [@B175]; [@B133]). In the adult hippocampus (DG), SGZ radial glia-like cells give rise to proliferative non-radial-like populations that differentiate into neuroblasts. Upon differentiation, these neuroblasts develop into granule cells ([@B133]). The embryonic origin of adult precursors in the DG in rodents was recently traced to a common Hopx-positive precursor population that is responsible for generating both developmental and AN, with the precursors not undergoing a lineage specification change during any stage of development ([@B19]). Non-mammalian Vertebrates: In contrast to mammals, non-mammalian vertebrates including certain fish and salamander species display a remarkable amount of neurogenic capacity in the adult. More than a dozen constitutive neurogenic zones have been described in the adult teleost ([@B60]; [@B106]), and while constitutive neurogenesis is limited to the forebrain in the newt ([@B18]) and the forebrain and ventricular zone in the axolotl ([@B102]), neuronal loss in these species following injury leads to complete regeneration ([@B20]; [@B125]; [@B18]; [@B159]). This latter capacity is reminiscent of, albeit less efficacious, reparative recruitment of quiescent progenitors found in rodents ([@B15]; [@B158]; [@B103]). Implications for Designing Brain Repair Strategies: The limited ability of AN in mammals to enable neural repair could be due to a presence of reduced number of NSCs, available progenitors that maybe fate-restricted or strong inhibitory cues from glia. As mentioned, studies focused on naturally occurring neurogenic process that are present in lower vertebrates can yield important insights into why those mechanisms are restricted in mammals ([@B22], [@B21]). Evidence for the presence of evolutionary conserved genes related to regeneration as revealed by recent genome sequencing of species with enhanced regenerative capacities and the development of techniques that make those species amenable to gene-editing ([@B72]; [@B75]; [@B44]; [@B120]) has paved the way for in-depth investigation of neurogenic molecular controls and their comparison across mammals and non-mammalian species to design novel therapies. Created with [Biorender.com](https://biorender.com/).](fcell-08-00116-g001){#F1}

Adult Neurogenesis in the Mammalian Brain {#S2}
=========================================

Evidence of Adult Neurogenesis in Mammals: A Brief History {#S2.SS1}
----------------------------------------------------------

Initial anatomical evidence of the existence of AN in mammals did not arrive until the 1960s when, using thymidine-H^3^ autoradiographic techniques, Joseph Altman reported evidence of the formation of newborn neurons in the adult brain ([@B2], [@B3]; [@B4], [@B5]). Follow-up electron microscopic studies extended support to the claim of radio-labeled cells as being neuronal ([@B80]), still, a lack of use of definitive neuronal markers to co-label radio-labeled cells and a failure to replicate this in non-human primates ([@B137]; [@B42]) prevented the field from reaching consensus.

Almost a decade after Altman's initial findings, Fernando Nottebohm, following up on his discovery of sexually dimorphic and seasonally regulated song-control system in the songbird ([@B119]; [@B118]), crucially demonstrated adult-born cells' neuronal identity and functional integration into adult circuits ([@B59]; [@B128]; [@B7]). Soon after, the glial nature of NSCs in songbirds was described ([@B8]), which was followed by similar observations in the mammalian SVZ ([@B40]) and hippocampus ([@B155], [@B154]). Later, the isolation of mitogen-responsive multipotent cells and successful induction of reactive neurogenesis suggested continuance of prenatal permissive regenerative programs into the adult mammalian brain ([@B143]; [@B97]; [@B100]; [@B123]). Finally, AN in the SVZ and hippocampus was shown to exist in humans ([@B46]; [@B163]; [@B47]).

### Adult Neurogenesis in the Sub-Ventricular Zone {#S2.SS1.SSS1}

Initial characterization of the adult human SVZ by Alvarez-Buylla et al., reported a ribbon of astrocytes lining the lateral ventricles with few surrounding proliferating cells ([@B152]). In particular, the human SVZ was reported to lack the cellular organizational structure and rostral migratory stream (RMS) characteristics of its rodent counterpart ([Figure 1](#F1){ref-type="fig"}, legend). A follow-up study by the same group reported strong expression of immature cell markers and RMS in the infant human SVZ, both of which sharply declined after birth ([@B151]). In addition, a novel migratory stream to the cortex was described in the infant brain ([@B151]). In contrast, another group found robust SVZ proliferation and a RMS containing glial cells, proliferating cells and neuroblasts organized around a lateral ventricular extension reaching the olfactory bulb (OB) in the adult ([@B37]; [@B79]). These disparate adult human data underscore the importance of applying more reliable, species-specific progenitor/immature cell markers and optimizing methodological approaches for identifying NSCs (see also below). From a therapeutic perspective, the existence of SVZ neurogenesis in humans could have important implications for neurodegenerative disorders as neuroblasts were recently shown to migrate to and differentiate into interneurons in the striatum ([@B47]) \[but also see [@B38]\] and carbon-14 birth-dating studies have suggested that adult-born striatal neurons might be preferentially depleted in Huntington's disease (HD) ([@B47]). Moreover, in animals models of PD, stimulation of SVZ precursors has been shown to rescue dopamine (DA) mediated behaviors ([@B164]; [@B10]).

### Adult Neurogenesis in the Hippocampal Dentate Gyrus {#S2.SS1.SSS2}

Whether the adult human hippocampus contains self-renewing NSCs is a topic of much interest. [@B46] initially reported newly generated BrdU-labeled cells in the human DG that co-expressed neuronal markers. This finding was corroborated by studies demonstrating the presence of neural progenitors in surgically excised brain specimens ([@B148]; [@B124]) and carbon-14 birth-dating studies that revealed substantial DG neuronal turnover ([@B163]). Recently, [@B27] also found preserved DG neurogenesis in individuals 14--79 years of age, with older individuals having a smaller quiescent progenitor pool. The existence of lifelong hippocampal AN was further confirmed in two very recent studies that examined neurogenesis throughout normal and pathological aging in AD patients ([@B109]) and in individuals with mild cognitive impairment ([@B171]), with findings suggesting impaired neurogenesis in both conditions. This is not surprising since an enhanced DG neurogenic capacity has been linked to reduced susceptibility to cognitive impairments in patients with AD pathology ([@B29]) and enhancing hippocampal neurogenesis improved cognition in an AD mouse model ([@B34]). In stark contrast, other groups have observed a sharp decline in proliferating cells in childhood, observing only sparse number of proliferating cells in the adult hippocampus that were of microglia lineage ([@B38]). In addition, [@B162], using DCX and PSA-NCAM to label immature neurons, found a sharp reduction in hippocampal neurogenesis in childhood observing no new neurons in the adult. Intriguingly, the authors found that both these markers, which are widely used to identify neurogenesis in other species, can label mature neurons and glial cells in humans. Marker expression can depend on tissue preservation techniques and DCX is known to be sensitive to postmortem breakdown ([@B26]) posing significant challenges to cross-study comparisons. Future studies could benefit by allocating efforts to documenting the clinical profile and mode of death of patients as both these factors can drastically influence neurogenesis rates. In addition, applying quality control procedures, including minimizing postmortem delay, optimizing brain fixation methods to preserve neuronal morphology and marker expression, standardization of protocols for identification of neurogenic neurons and examination of gene expression patterns, along with development of more specific markers of neurogenic neurons in humans may be beneficial.

Adult Neurogenesis in the Non-mammalian Brain: Similarities to Adult Mammalian Neurogenesis {#S2.SS2}
-------------------------------------------------------------------------------------------

Several similarities exist between mammalian and non-mammalian species regarding AN. These include the sites of neurogenesis \[the ventricular lining within the telencephalon appears to be the site of origin of new neurons in many mammalian and non-mammalian species ([@B59]; [@B40]; [@B57]; [@B147])\], identity of neurogenic progenitors as well as the molecular machineries that regulate proliferation of NSCs. Like in mammals ([@B40]), some progenitor populations in birds, fishes and amphibians also have glial characteristics ([@B8]; [@B147]; [@B87]). Moreover, molecular controls governing quiescence of NSCs show remarkable conservation between vertebrate species: e.g., Notch signaling has been shown to regulate radial glial quiescence in zebrafish ([@B6]), newt ([@B87]) and adult mouse ([@B74]) and transcription factors Id1 and Fezf2 that are associated with increased quiescence in adult mouse NSCs ([@B112]) have also been identified in zebrafish ([@B17]; [@B145]). Intriguingly, Ascl1 upregulation has been linked to the activation of the retinal latent progenitors, Muller glia, in zebrafish during retinal regeneration following lesions ([@B138]) and forced overexpression of Ascl1 in Muller glia in young mice coaxes these progenitors toward a neurogenic fate ([@B174]) rather than the gliogenic fate that is normally seen in older mice ([@B41]). Comparative studies of species can thus yield important insights into the biology of AN and be informative for therapeutic strategies that harness AN potential of tissue repair ([@B88]; [Figure 1](#F1){ref-type="fig"}).

Neural Transplantation as Cell-Based Therapy {#S3}
============================================

On the other hand, transplantation of NSCs or progenitors to replace diseased neurons is an alternate strategy that comes with the opportunity of directing therapy to brain regions where it is most needed ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Also, the self-renewing attribute and migratory nature of NSCs/progenitors make them attractive therapeutic candidates in the setting of diffuse damage to the brain.

###### 

Summary of select studies involving cell-transplant based repair strategies in *in vivo* pre-clinical neurodegenerative disease models.

  Repair strategy                  References         Type of cell grafted/manipulated                                                            Disease/model                           Functional impact
  -------------------------------- ------------------ ------------------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------------------------------------
  Fetal-tissue based               ([@B24])           Fetal ventral midbrain tissue                                                               PD/rat 6-OHDA                           Restoration of DA innervation and motor improvement
                                   ([@B76])           Fetal striatal tissue                                                                       HD/rat Ibotenic-acid                    Reduction in locomotor and metabolic hyperactivity
                                   ([@B98]; [@B55])   Fetal substantia nigra and septal nuclei                                                    Aging, hippocampal lesions              Improved motor coordination and spatial learning
                                   ([@B56]; [@B51])   Fetal tissue                                                                                Motor, visual cortex                    Long range, synaptic, functional integration with host circuitries
  MSCs-based                       ([@B69])           mBM-MSCs                                                                                    PD/rat 6-OHDA                           Cells migrate to lesioned hemisphere and differentiate into neurons
                                   ([@B14])           hBM-MSCs                                                                                    PD/rat 6-OHDA                           Reduction in motor impairments, regeneration of DA terminals
                                   ([@B92])           hAD-MSCs                                                                                    HD/rat QA-lesion, mouse R6/2            Improved motor performance, reduced huntingtin aggregates
                                   ([@B94])           hBM-MSCs                                                                                    HD/mouse QA-lesion, R6/2                Improved motor performance in QA-lesion model
                                   ([@B157])          hMSCs                                                                                       AD/mouse Aβ treated                     Increased autophagy and Aβ clearance
                                   ([@B58])           VEGF overexpressing BM-MSCs                                                                 AD/mouse APPswe/PS1 double transgenic   Increased vascularization, cognition, decreased Aβ plagues
                                   ([@B84])           ALS-hBM-MSCs                                                                                ALS/mouse SOD1^G93A^                    Increased lifespan, increased MN survival
                                   ([@B85])           hAD-MSCs                                                                                    ALS/mouse SOD1^G93A^                    Release of growth factors, increased life span
  hESCs-based                      ([@B90])           hESC-DA neurons                                                                             PD/mouse, rat 6-OHDA, monkey MPTP       Long term survival and motor restoration
                                   ([@B61])           hESC-DA neurons                                                                             PD/rat 6-OHDA                           Motor restoration comparable to human fetal grafts
                                   ([@B166])          Inhibitory opsin-expressing hESC-DA neurons                                                 PD/mouse 6-OHDA                         Light-induced silencing of grafts re-introduced motor defects
                                   ([@B33])           CRISPR-engineered DREADD expressing hESC-DA neurons                                         PD/mouse 6-OHDA                         Control of motor behaviors by CNO
                                   ([@B11])           hESC-striatal progenitors                                                                   HD/rat QA-lesion                        DARPP32 + differentiation
                                   ([@B101])          hESC-striatal progenitors                                                                   HD/mouse QA-lesion                      Correction of locomotive deficits and circuit integration
                                   ([@B50])           hESC-striatal progenitors                                                                   HD/rat QA-lesion                        Long-range circuit integration
                                   ([@B48])           hESC-cortical progenitors                                                                   AD/chimeric APP/PS1 mouse               Susceptibility of human neurons to Tau
                                   ([@B183])          hESC-basal forebrain cholinergic neurons                                                    AD/mouse 5XFAD, APP/PS1                 Improvement in learning and memory
                                   ([@B146])          hESC-MNP                                                                                    SCI/rat                                 Improvement in motor function
                                   ([@B180])          hESC-MNP                                                                                    ALS, SMA, SCI                           Increased growth factor secretion
  iPSCs-based                      ([@B66])           DA neurons differentiated from patient fibroblasts                                          PD/rat 6-OHDA                           Correction of AMPH-induced rotation behavior
                                   ([@B150])          DA progenitors differentiated from human PSCs                                               PD/rat 6-OHDA, monkey MPTP              Restoration of motor deficits
                                   ([@B82])           DA neurons differentiated from healthy and PD fibroblasts                                   PD/monkey MPTP                          Long-term survival of DA cells. Increase in spontaneous movement.
                                   ([@B83])           Healthy or idiopathic PD-iPSCs differentiated from fibroblasts and peripheral blood cells   PD/mouse α-Synuclein, rat 6-OHDA        Lack of α-Synuclein accumulation. Motor improvement
                                   ([@B77])           CAG-repeat HD-iPSCs                                                                         HD/rat QA-lesion                        Initial behavioral recovery. Development of HD pathology.
                                   ([@B9])            CAG-repeat-corrected HD-iPSCs                                                               HD/mouse R6/2                           Rescue of pathogenic HD signaling
                                   ([@B110])          Mouse iPSCs                                                                                 HD/rat QA-lesion                        Improved learning and memory
                                   ([@B31])           Mouse iPSCs                                                                                 AD/mouse 5XFAD                          Reduced Aβ plaque, improved cognition
                                   ([@B54])           hiPSCs- cholinergic neurons                                                                 AD/mouse PDAPP                          Improved spatial memory
                                   ([@B135])          hiPSCs-MNP                                                                                  ALS/rat SOD1^G93A^                      Motor neuron generation
                                   ([@B117])          hiPSCs-NSC                                                                                  ALS/mouse SOD1^G93A^                    Improved neuromuscular function, reduced motor neuron loss
  *In vivo* direct reprogramming   ([@B173])          Exogenous human astrocytes. Endogenous mouse striatal astrocytes                            PD/mouse 6-OHDA                         Conversion into DA neurons
                                   ([@B144])          Endogenous mouse striatal astrocytes                                                        PD/mouse 6-OHDA                         Conversion into DA neurons. Correction of gait
                                   ([@B129])          Endogenous midbrain and striatal NG2 glia                                                   PD/mouse 6-OHDA                         Conversion into PV neurons
                                   ([@B115])          Endogenous striatal astrocytes                                                              Aging/mouse                             Conversion into neuroblasts and mature neurons
                                   ([@B62])           Endogenous cortical astrocytes and NG2 glia                                                 AD, Stab-injury/mouse                   Conversion into glutamatergic and GABA neurons
                                   ([@B167])          Endogenous and exogenous astrocytes                                                         SCI/T8 hemi-section mouse               Neurogenesis and conversion into GABA neurons
                                   ([@B43])           Endogenous mouse neuroblasts                                                                Demyelination/cuprizone-induced         Conversion into myelin producing oligodendrocytes
                                   ([@B172])          Endogenous mouse NG2 glia                                                                   Mouse                                   Conversion into glutamatergic and GABA neurons

MSC, Mesenchymal Stem Cell; hESC, human Embryonic Stem Cell; hiPSC, human induced Pluripotent Stem Cell; PD, Parkinson's Disease; 6-OHDA, 6-hydroxydopamine; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; HD, Huntington Disease; QA, Quinolinic Acid; R6/2, Huntingtin transgene insertion 62; hBM, human bone marrow; hAD, human Adipose; Aβ, beta-amyloid; AD, Alzheimer's Disease; APPswe/PS1, amyloid beta precursor protein/presenilin 1; 5XFAD, mice express human APP and PSN1 transgenes with a total of five AD-linked mutations; PDAPP, APP expressed under PDGF promoter; ALS, amyotrophic lateral sclerosis; SOD1, superoxide dismutase 1; SCI, spinal cord injury; SMA, spinal muscular atrophy.

Fetal and Embryonic Tissue-Based Transplants in Pre-clinical Models and Clinical Trials {#S3.SS1}
---------------------------------------------------------------------------------------

Initial proof-of-concept transplantation studies carried out during 70 and 80s demonstrated long-term viability of grafted neural tissue and evidence for functional replacement for missing neurons. In animal models of PD and HD, transplanted fetal rat substantia nigra tissue established connections with host striatum and reversed motor and metabolic deficits ([@B130]; [@B76]). Additional support came from the long-term survival of human fetal neural tissue in monkeys ([@B139]), that led to the commencement of transplantation of fetal tissue into the striatum of PD patients ([@B95]; [@B165]). Intriguingly, the initial open-label clinical trials demonstrated restoration of DA synthesis resulting in significant and long-lasting clinical improvements of motor function ([@B67]; [@B132]). Though variable clinical efficacy was observed, the ability of allografts to survive, integrate and function in diseased host environment, in some cases up to 20 years ([@B16]), was in itself an exciting finding. Subsequent double-blinded, placebo controlled clinical trials, however, failed to reveal definitive results and long-term follow up studies revealed the development of α-synuclein aggregates in grafted fetal neurons ([@B89]) and graft-induced dyskinesias ([@B52]; [@B64]; [@B121]), effects later attributed to heterogenous spread of transplanted cells and/or graft contamination by serotonergic cells ([@B134]). In addition, early withdrawal of immunosuppression, severe phenotype of transplanted patients and grafts' non-innervation of the ventral striatum were identified as some of the limiting factors. Based on these findings, a new multi-center trial with fetal-based transplantation to PD patients is currently underway that hopes to address these concerns ([@B108]; [@B86]). Therapeutic potential of neural transplantation was similarly first explored for HD in rodent and non-human primate models ([@B177]; [@B131]; [@B81]), the positive results of which led to fetal striatal implantation in patients in the mid- to late-90s ([@B13], [@B12]; [@B68]). However, disease-like neuronal degeneration of grafted tissue upon postmortem analysis raised uncertainty about this approach ([@B36]; [Table 1](#T1){ref-type="table"}).

Limitations of Using Fetal and Embryonic Origin Cell-Based Transplantation Strategies {#S3.SS2}
-------------------------------------------------------------------------------------

It is worth mentioning here that both PD and HD, at least in their earlier stages, involve relatively specific cellular and regional pathologies: nigrostriatal DA neurons in PD and striatal medium spiny neurons in HD, making them suitable to tissue grafts dissected from fetal regions that contain the target cell population. However, it should also be kept in mind that pathologies in these conditions are not region-specific. For instance, in PD, non-DA and non-motor symptoms can cause significant disability, especially in patients with advanced pathology ([@B32]) and while striatal pathology dominates initial stages of HD, cell loss in the motor and cingulate cortices correlates with the degree of motor and mood dysfunction characteristic of the disease in later stages ([@B170]). Therefore, to alleviate the full repertoire of advanced disease symptomatology, adjuvant therapy for secondary disease processes maybe required. Indeed, widespread brain degenerative changes have been proposed to offset therapeutic efficacy of an otherwise viable graft ([@B93]). Such a strategy may also not be applicable to disorders of diffuse pathology such as stroke, AD, SCI, and ALS, that involve pathological alterations in multiple neuronal and glial cellular phenotypes and brain regions. Lastly, the most obvious limitation to fetal transplants is the limited availability of graft sources which have traditionally been derived from human embryos causing significant logistical and ethical concerns.

Precision Therapeutics {#S4}
======================

Human Embryonic and Induced Pluripotent Stem Cell Technologies {#S4.SS1}
--------------------------------------------------------------

Given the variable clinical efficacy, risk of contamination by non-specific cell types and ethical concerns associated with fetal grafts, alternative transplant sources have been sought to boost endogenous reparative mechanisms. Recently, pluripotent stem cells (PSCs) ([@B63]; [@B49]; [@B105]) including hESCs ([@B169]; [@B142]) derived from pre-implantation embryos, and hiPSCs ([@B168]; [@B182]; [@B127]) that are reprogrammed from somatic cells using a defined cocktail of transcription factors, have attracted tremendous interest in the field of regenerative medicine. Use of autologous hiPSCs can also overcome immune mismatch-mediated graft rejection and circumvent ethical and logistical issues associated with the use of hESCs. While hiPSC technology is by design usable to treat donor patients limiting its cost-effectiveness and scalability ([@B111]), hypo-immunogenicity in hiPSCs was recently achieved via inactivation of the major histocompatibility complex (MHC) and overexpression of the transmembrane protein CD47 ([@B39]), potentially conferring a remarkable universal donor capability to hiPSCs ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

Genome-Editing {#S4.SS2}
--------------

The development of biotechnology allowing generation of hiPSCs from non-viral techniques and gene-editing tools that enable site-specific corrections of disease-causing gene mutations have made genome-edited hiPSC-based cell therapy an ideal choice in the field of precision therapeutics. Using genome-editing tools, such as zinc finger nucleases (ZFNs) ([@B23]), TAL effector nucleases ([@B25]) and the more specific clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system ([@B104]), that enable precise corrections of deleterious mutations, genome corrected-iPSCs are now being generated. Already, advances have led to generation of engineered cells that are able to deliver therapeutic factors and that carry minimal risks of tumorigenicity in preclinical models of PD ([@B90]; [@B61]; [@B65]; [@B166]; [@B82]; [@B156]). Using ZFNs, generation of isogenic disease and control hiPSCs from PD patients' cortical neurons carrying the α-synuclein mutations A53T ([@B35]) and LRRK2 ([@B141]) and their insertion into hESCs ([@B160]) have been described. Lately, CRISPR/Cas system has been used to correct α-synuclein mutations in PD hiPSCs ([@B70]; [@B161]), remove HTT-repeat expansion mutation in HD hiPSCs ([@B181]) and correct mutations in presenilin (PSEN) in AD basal forebrain cholinergic neurons ([@B122]). While majority of these studies have employed *ex vivo* manipulation of hiPSCs, successful *in vivo* gene editing of post mitotic cells, as has been shown in five-familial AD and amyloid precursor protein (APP) knock-in mice ([@B126]), has opened up the tantalizing prospect of eliminating the need for cell transplants for brain repair. In theory, *in vivo* gene editing is a similar concept to the one used for *in vivo* direct reprogramming in which non-neuronal cells are converted into disease-specific neurons directly *in situ* with preclinical studies showing successful integration of reprogrammed cells into host circuits within the cerebral cortex ([@B62]), striatum ([@B172]), midbrain ([@B173]) and the spinal cord ([@B167]) in heterogenous disease contexts ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

Discussion {#S5}
==========

Applying a Multi-Pronged Strategy for Repair of Neural Tissue {#S5.SS1}
-------------------------------------------------------------

Alterations in AN appear to be a common feature in many neurological and psychiatric disorders ([@B149]; [@B179]; [@B116]; [@B136]). Studies in experimental models can yield important insights into AN biology including its potential for cell replacement in disease and injury contexts ([@B176]; [@B114]). Yet to achieve successful tissue restoration, a combinatorial therapeutic strategy might be required that includes boosting of endogenous neurogenic processes, *in vivo* genome-correction of endogenously generated NSCs/progenitors/mature neurons, transplantation of *ex vivo* gene-corrected neurons and the delivery of neurotherapeutic factors. Transplantation of fate-restricted progenitors that retain the capability to migrate and differentiate into mature neurons and functionally integrate into existing circuits has the benefit of decreasing the number of transplants and chances of developing non-specificity issues. Still, multiple cellular phenotypes might be required to construct a therapeutically efficacious graft, whose composition must be geared toward correcting primary genetic deficits and secondary phenotypes. Transplant composition for chronic neurodegenerative diseases, especially in advanced stages, might require a greater dependence on exogenous cells due to the extensive damage to host tissue, while also attempting to correct mutations in remaining diseased neuronal populations. Acute injuries, on the other hand, would require a greater role for neurotrophic factors and modification of extracellular matrix to facilitate regeneration of existing tissue, while at the same time replacing lost or damaged neural populations by promoting endogenous neurogenesis and transplanting fate-restricted precursors and/or reprogrammed mature neurons. Given the above, perhaps the most effective approach while designing cell-based therapy might be to adopt a multi-pronged strategy that cumulatively addresses the shortcomings of the above-mentioned tissue restoration strategies and that is tailored to the brain disease in hand.
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